[Bone and calcium metabolism associated with malignancy. Endocrine therapy of breast cancer.]

[Bone and calcium metabolism associated with malignancy. Endocrine therapy of breast cancer.] Clin Calcium. 2018;28(11):1509-1513 Authors: Yamashita H Abstract Estrogen receptor(ER)-positive breast cancer accounts for approximately 80%of all breast cancers. The basic concept of endocrine therapy is to deplete estrogen(LH-RH agonist and aromatase inhibitor)and inhibit the action of estrogen against estrogen-dependent growth in ER-positive breast cancer. Recently, new molecular targeting agents, including an mTOR inhibitor and a CDK4/6 inhibitor, have been used in combination with endocrine therapy for the treatment of ER-positive metastatic breast cancer. PMID: 30374008 [PubMed - in process]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Calcium Source Type: research